These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32414722)

  • 1. Decompensated cirrhosis is the commonest presentation for NAFLD patients undergoing liver transplant assessment.
    Hussain A; Patel PJ; Rhodes F; Srivastava A; Patch D; Rosenberg W
    Clin Med (Lond); 2020 May; 20(3):313-318. PubMed ID: 32414722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.
    Wong CR; Njei B; Nguyen MH; Nguyen A; Lim JK
    Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1061-1069. PubMed ID: 28960360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
    Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
    Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Natural History of NAFLD, a Community-Based Study at a Large Health Care Delivery System in the United States.
    Nyberg LM; Cheetham TC; Patton HM; Yang SJ; Chiang KM; Caparosa SL; Stern JA; Nyberg AH
    Hepatol Commun; 2021 Jan; 5(1):83-96. PubMed ID: 33437903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case-control study.
    Unger LW; Herac M; Staufer K; Salat A; Silberhumer G; Hofmann M; Trauner M; Rasoul-Rockenschaub S; Soliman T; Reiberger T; Berlakovich GA
    Eur J Gastroenterol Hepatol; 2017 Mar; 29(3):309-316. PubMed ID: 27922486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
    Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease after liver transplantation in patients with non-alcoholic steatohepatitis and cryptogenic cirrhosis: the impact of pre-transplant graft steatosis.
    Eshraghian A; Nikeghbalian S; Kazemi K; Shamsaeefar A; Geramizadeh B; Malek-Hosseini SA
    HPB (Oxford); 2020 Apr; 22(4):521-528. PubMed ID: 31431413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver transplantation of patients with cryptogenic cirrhosis: clinical characteristics and outcome.
    Marmur J; Bergquist A; Stål P
    Scand J Gastroenterol; 2010; 45(1):60-9. PubMed ID: 20030578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis.
    Bengtsson B; Stål P; Wahlin S; Björkström NK; Hagström H
    Liver Int; 2019 Jun; 39(6):1098-1108. PubMed ID: 30829446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
    Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
    Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease.
    Canbay A; Kachru N; Haas JS; Sowa JP; Meise D; Ozbay AB
    Aliment Pharmacol Ther; 2020 Oct; 52(7):1185-1194. PubMed ID: 33016540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic steatohepatitis: the new frontier for liver transplantation.
    Bzowej NH
    Curr Opin Organ Transplant; 2018 Apr; 23(2):169-174. PubMed ID: 29356708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics of non-alcoholic fatty liver disease in Chinese adult hypopituitary patients.
    Yuan XX; Zhu HJ; Pan H; Chen S; Liu ZY; Li Y; Wang LJ; Lu L; Yang HB; Gong FY
    World J Gastroenterol; 2019 Apr; 25(14):1741-1752. PubMed ID: 31011258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Only one-third of referrals for fatty liver disease are on time: real-world study reveals opportunities to avoid unnecessary and delayed referrals.
    Lindvig KP; Wernberg CW; Kjaergaard M; Thorhauge KH; Alnor AB; Thiele M; Krag A
    Scand J Gastroenterol; 2022 Dec; 57(12):1478-1485. PubMed ID: 35793386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Portal Hypertension Complications Are Frequently the First Presentation of NAFLD in Patients Undergoing Liver Transplantation Evaluation.
    Nagpal SJ; Kabbany MN; Mohamad B; Lopez R; Zein NN; Alkhouri N
    Dig Dis Sci; 2016 Jul; 61(7):2102-7. PubMed ID: 26993824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014.
    Kim D; Cholankeril G; Li AA; Kim W; Tighe SP; Hameed B; Kwo PY; Harrison SA; Younossi ZM; Ahmed A
    Liver Int; 2019 Sep; 39(9):1661-1671. PubMed ID: 31081997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease.
    Than NN; Ghazanfar A; Hodson J; Tehami N; Coldham C; Mergental H; Manas D; Shah T; Newsome PN; Reeves H; Shetty S
    QJM; 2017 Feb; 110(2):73-81. PubMed ID: 27634970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nash Up, Virus Down: How the Waiting List Is Changing for Liver Transplantation: A Single Center Experience from Italy.
    Ferrarese A; Battistella S; Germani G; Russo FP; Senzolo M; Gambato M; Vitale A; Cillo U; Burra P
    Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208613
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design.
    Allen AM; Therneau TM; Ahmed OT; Gidener T; Mara KC; Larson JJ; Canning RE; Benson JT; Kamath PS
    J Hepatol; 2022 Nov; 77(5):1237-1245. PubMed ID: 35843374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alcoholic liver disease presents at advanced stage and progresses faster compared to non-alcoholic fatty liver diseas.
    Shoreibah M; Raff E; Bloomer J; Kakati D; Rasheed K; Kuo YF; Singal AK
    Ann Hepatol; 2016; 15(2):183-9. PubMed ID: 26845595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.